Gülden Bilican

Dr. Gülden Bilican


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
GBGülden Bilican
Gülden Bilican
TKTarkan Karakan
Tarkan Karakan
OGOdul Egritas Gurkan
Odul Egritas Gurkan
MCMehmet Cindoruk
Mehmet Cindoruk
CHCharlotte Hedin
Charlotte Hedin
SHStephan Haas
Stephan Haas
Objective: Intestinal ultrasound (IUS) is increasingly valued as a noninvasive tool for inflammatory bowel disease (IBD) management, offering real-time, radiation-free assessment of bowel wall thickness, vascularity, and complications. While IUS is widely adopted in Europe, data on its use in Turkey is scarce. This study aims to address this gap. Methods: A nationwide, cross-sectional survey was conducted targeting 817 adult and 150 pediatric gastroenterologists in Turkey. The survey included 26 structured questions on demographics, familiarity with and use of IUS, and barriers to implementation. Results: A total of 191 gastroenterologists participated in this survey, with 56% being adult gastroenterologists (n = 107) and 44% pediatric gastroenterologists (n = 84). Regarding whether they participated in IUS training, 73% (n = 140) of the 191 respondents stated they had not received training. There were notable differences in how IUS was utilized among gastroenterologists: 29% (n = 31) of adult gastroenterologists performed IUS independently, compared to just 2% (n = 2) of pediatric gastroenterologists (p < 0.001). In total, 63% (n = 67) of adult gastroenterologists and 46% (n = 39) of pediatric gastroenterologists reported not using IUS. Altogether, 94% (n = 179) emphasized the necessity of educational opportunities, and 86% (n = 165) favored national guidelines. Conclusions: Our findings reveal that the current application of IUS in Turkey fails to correspond with its expected advantages in managing IBD. Limited educational opportunities are a major challenge, emphasizing the necessity for coordinated educational programs and national guidelines. The expanded adoption of the IUS might significantly improve Turkey’s management of IBD. What is known: Intestinal ultrasound (IUS) is a non-invasive, cost-effective, and reliable imaging method increasingly recognized for its utility in diagnosing and monitoring inflammatory bowel disease (IBD). What is new: This is the first national survey assessing the awareness, usage patterns, and barriers to the adoption of IUS among gastroenterologists in Turkey. The study highlights significant gaps in training opportunities while also identifying strategies to promote IUS integration into routine clinical practice. The findings may encourage similar efforts in other regions where IUS remains underutilized, ultimately improving IBD management and patient outcomes globally.

22 May 2026 in BMC Gastroenterology
Verified
Journal Article
Open access
GBGülden Bilican
Gülden Bilican
NNNurulamin M. Noor
Nurulamin M. Noor
SHStephan L. Haas
Stephan L. Haas
GPGrigorios Petrousis
Grigorios Petrousis
DKDerya Kirman
Derya Kirman
TKTarkan Karakan
Tarkan Karakan
Ulcerative colitis (UC) is a chronic inflammatory bowel disease marked by relapsing mucosal inflammation. Recent data indicate that subclinical metabolic disturbances persist even in patients who have achieved remission. However, the temporal evolution of these molecular alterations remains poorly defined. This study examined how disease duration shapes systemic metabolic and lipidomic remodeling in UC. Plasma samples from 58 UC patients in clinical remission and 70 age- and sex- matched healthy controls (HC) were analyzed using integrated untargeted gas chromatography-mass spectrometry (GC-MS) and liquid chromatography-mass spectrometry (LC-MS). Patients were stratified by disease duration (≤ 2 years vs. > 2 years). Multivariate and univariate analyses, including partial least squares discriminant analysis (PLS-DA), variable importance in projection (VIP) scoring, and t-tests or Mann-Whitney U test (p < 0.05), were applied, and pathway enrichment was performed using the Kyoto Encyclopedia of Genes and Genomes (KEGG) database. UC patients showed distinct plasma metabolomic and lipidomic signatures compared with HC, with 15 metabolites and 126 lipid species significantly altered. Reduced pyruvic and lactic acids, together with disrupted fatty-acid and amino-acid metabolism, suggested impaired energy and redox homeostasis. Lipidomic profiling revealed broad disturbances across phosphatidylcholines, lysophosphatidylcholines, phosphatidylethanolamines, sphingomyelins, diacylglycerols, and triglycerides, reflecting persistent oxidative and inflammatory imbalance. Stratification by disease duration revealed progressive remodeling, particularly within amino-acid pathways and sphingolipid metabolism. Even during remission, UC exhibits systemic metabolic disequilibrium that evolves with disease chronicity. These time-dependent changes could guide the identification of metabolic biomarkers for disease monitoring and personalized therapeutic strategies.